Diametric Capital LP Makes New $108,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR)

Diametric Capital LP bought a new stake in Atyr PHARMA INC (NASDAQ:ATYR) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 29,812 shares of the company’s stock, valued at approximately $108,000.

Other hedge funds also recently modified their holdings of the company. Alterna Wealth Management Inc. bought a new position in Atyr PHARMA during the 4th quarter valued at $36,000. Victory Capital Management Inc. purchased a new stake in shares of Atyr PHARMA in the fourth quarter valued at about $37,000. Raymond James Financial Inc. bought a new position in shares of Atyr PHARMA during the fourth quarter valued at about $39,000. JPMorgan Chase & Co. boosted its holdings in Atyr PHARMA by 52.0% during the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after purchasing an additional 10,754 shares during the last quarter. Finally, Farther Finance Advisors LLC bought a new stake in Atyr PHARMA in the 4th quarter worth about $88,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ATYR. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Leerink Partners assumed coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price objective on the stock. Cantor Fitzgerald assumed coverage on Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a report on Friday, March 14th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Atyr PHARMA currently has a consensus rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Price Performance

Shares of NASDAQ ATYR opened at $2.96 on Thursday. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The stock has a fifty day simple moving average of $3.61 and a two-hundred day simple moving average of $3.21. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66. The firm has a market cap of $263.02 million, a price-to-earnings ratio of -3.15 and a beta of 0.98.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. Analysts anticipate that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.